PHVS Stock — Pharvaris N.V.: Cash, EV, Pipeline

Share price

$36.37

Market cap

$2,533.8M

Cash

$466.4M

Enterprise value

$2,067.4M

Balance sheet

Cash	$466.4M
Debt	$0.0M
Net cash	$466.4M
Enterprise value	$2,067.4M
Basic shares	69.7M shares
Fully diluted shares	69.2M shares
Fully diluted market cap	$2,515.4M
Cash per share	$6.69

Cash figures as of 2026-05-11. Database snapshot: 2026-09-21.

Price history

Loading PHVS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 24, 2026	Deucrictibant	Phase 3	Hereditary Angioedema (HAE)	—
Jul 13 - Aug 24	deucrictibant	Phase 3	Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II	—
Jul 13 - Aug 24	Deucrictibant	Phase 3	Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)	—
Jan 12 - Feb 23	Deucrictibant	Phase 3	Hereditary Angioedema (HAE)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Deucrictibant IR

Phase 3 · Active Modality: oral capsule

Target bradykinin B2 receptor

Indications

On-demand treatment of hereditary angioedema (HAE) attacks (Phase 3)

Status note Immediate-release capsule. Topline data from RAPIDe-1, RAPIDe-2, and RAPIDe-3 released; RAPIDe-2 open-label extension ongoing. No NDA submission or PDUFA timing stated in 20-F excerpts.

Deucrictibant XR

Phase 3 · Active Modality: oral tablet (extended-release)

Target bradykinin B2 receptor

Indications

Prophylactic treatment of HAE attacks (Phase 3)

Status note Extended-release tablet. CHAPTER-1 proof-of-concept and safety data released; pivotal Phase 3 CHAPTER-3 ongoing; CHAPTER-4 open-label extension ongoing. No topline timing stated in 20-F excerpts.

Per-asset detail extracted from the 20-F filed 2026-04-02. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	deucrictibant
Lead indication	Hereditary Angioedema
Lead phase	Phase 3
Active trials	4
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05396105	Phase 3	Enrolling by invitation	Sponsor	PHVS	—	Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II	—
NCT07266805	Phase 3	Recruiting	Sponsor	PHVS	—	Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)	—
NCT06679881	Phase 3	Recruiting	Sponsor	PHVS	—	Hereditary Angioedema (HAE)	—
NCT06669754	Phase 3	Active, not recruiting	Sponsor	PHVS	—	Hereditary Angioedema (HAE)	—
NCT05834777	Phase 3	Recruiting	Collaborator	Vanderbilt University Medical Center	—	Intradialytic Hypotension	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Pharvaris Netherlands B.V. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	308,856	-178,000	1.75%	2026-08-14
OrbiMed Advisors	205,400	no change	0.13%	2026-08-14
ADAR1 Capital Management	105,528	no change	0.17%	2026-08-14
Baker Bros. Advisors	0	-375,000	0.00%	2026-08-14
Logos Global Management	0	-65,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

PHVS — Pharvaris N.V.